Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability
Larissa Mulka, David Annandale, Claire Richardson, Martin Fisher, Daniel Richardson
Sexually Transmitted Infections Mar 2016, 92 (2) 107; DOI: 10.1136/sextrans-2015-052262